These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11920591)

  • 1. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.
    Takasu S; Takahashi T; Okamoto S; Oriuchi N; Nakayashiki N; Okamoto K; Muramatsu H; Hayashi T; Nakahara N; Mizuno M; Wakabayashi T; Higuchi T; Endo K; Kozaki K; Miyaishi O; Saga S; Ueda R; Yoshida J; Yoshikawa K
    J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG; McKay MJ; Cvrljevic AN; Gan HK; Taylor C; Xu H; Smyth FE; Scott AM
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):572-8. PubMed ID: 20638193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
    Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
    FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
    Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
    Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.
    Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG
    J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody.
    Goldenberg A; Masui H; Divgi C; Kamrath H; Pentlow K; Mendelsohn J
    J Natl Cancer Inst; 1989 Nov; 81(21):1616-25. PubMed ID: 2795690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.
    Perera RM; Zoncu R; Johns TG; Pypaert M; Lee FT; Mellman I; Old LJ; Toomre DK; Scott AM
    Neoplasia; 2007 Dec; 9(12):1099-110. PubMed ID: 18084617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.
    Lee FT; O'Keefe GJ; Gan HK; Mountain AJ; Jones GR; Saunder TH; Sagona J; Rigopoulos A; Smyth FE; Johns TG; Govindan SV; Goldenberg DM; Old LJ; Scott AM
    J Nucl Med; 2010 Jun; 51(6):967-72. PubMed ID: 20484439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
    Panousis C; Rayzman VM; Johns TG; Renner C; Liu Z; Cartwright G; Lee FT; Wang D; Gan H; Cao D; Kypridis A; Smyth FE; Brechbiel MW; Burgess AW; Old LJ; Scott AM
    Br J Cancer; 2005 Mar; 92(6):1069-77. PubMed ID: 15770208
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.